DDInter1252 DDInter1752
Mycophenolic acid is a potent immunosuppressant agent that inhibits _de novo_ purine biosynthesis. It was derived from _Penicillium stoloniferum_, and has also shown antibacterial, antifungal and antiviral properties.. Mycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a calcineurin inhibitor (ciclosporin or tacrolimus) and prednisolone. This regimen can be used in place of the older anti-proliferative [azathioprine] due to its stronger immunosuppressive potency. However, mycophenolic acid treatment is more expensive and requires therapeutic drug monitoring to optimize efficacy and minimize toxicity.[A249180,A249185] Mycophenolic acid is available as enteric-coated tablets of delayed-release, in an effort to improve upper gastrointestinal adverse events by delaying mycophenolic
Drug-resistant bacteria, such as methicillin-resistant _Staphylococcus aureus_, vancomycin-resistant _Enterococcus faecium_, and penicillin-resistant _Streptococcus penumoniae_, represent a massive public health threat.[A199086, A199131] Tedizolid is a member of the oxazolidinone class of antibiotics, which includes the previously approved [linezolid] and is generally effective against multidrug-resistant Gram-positive bacteria. Tedizolid is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and is generally more effective and more tolerable than [linezolid].[L11232, A199086, A199050] Tedizolid was approved by the FDA on June 20, 2014, for sale by Cubist Pharmaceuticals as tedizolid phosphate (SIVEXTRO®). This product is currently available as both an oral tablet and as a powder for intravenous injection.
Mycophenolic acid {u} (Compound) resembles {v} (Compound) Mycophenolate mofetil
Mycophenolic acid {u} (Compound) treats {v} (Disease) systemic scleroderma
Mycophenolic acid {u} (Compound) binds {v} (Gene) IMPDH1
Mycophenolic acid {u} (Compound) upregulates {v} (Gene) UBE2L6
Mycophenolic acid {u} (Compound) downregulates {v} (Gene) SETD5
Mycophenolic acid {u} (Compound) causes {v} (Side Effect) Nervous system disorder
Mycophenolic acid {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ethotoin
Mycophenolic acid {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc gluconate
Mycophenolic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tigecycline
Mycophenolic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Candida albicans
Mycophenolic acid (Compound) resembles Mycophenolate mofetil (Compound)
Mycophenolic acid (Compound) treats systemic scleroderma (Disease)
Mycophenolic acid (Compound) binds IMPDH1 (Gene)
Mycophenolic acid (Compound) upregulates UBE2L6 (Gene)
Mycophenolic acid (Compound) downregulates SETD5 (Gene)
Mycophenolic acid (Compound) causes Nervous system disorder (Side Effect)
Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Ethotoin
Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Tigecycline
Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans